Ginkgo Bioworks Holdings, Inc. (DNA)
- Previous Close
0.8390 - Open
0.8400 - Bid 0.8100 x 2900
- Ask 0.8155 x 1100
- Day's Range
0.7890 - 0.8694 - 52 Week Range
0.7200 - 2.5450 - Volume
31,425,585 - Avg. Volume
35,913,853 - Market Cap (intraday)
1.781B - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4300 - Earnings Date Mar 1, 2024 - Mar 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.43
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
www.ginkgobioworks.comRecent News: DNA
Performance Overview: DNA
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNA
Valuation Measures
Market Cap
1.78B
Enterprise Value
1.18B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.59
Price/Book (mrq)
1.80
Enterprise Value/Revenue
5.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.76%
Return on Equity (ttm)
-65.81%
Revenue (ttm)
208.7M
Net Income Avi to Common (ttm)
-853.81M
Diluted EPS (ttm)
-0.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
840.44M
Total Debt/Equity (mrq)
23.75%
Levered Free Cash Flow (ttm)
-159.04M
Research Analysis: DNA
Company Insights: DNA
DNA does not have Company Insights